- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- May 2026
- 400 Pages
Global
From €4480EUR$4,949USD£3,845GBP
- Report
- May 2026
- 138 Pages
Global
From €2715EUR$2,999USD£2,330GBP
€3620EUR$3,999USD£3,107GBP
- Report
- March 2026
- 177 Pages
Global
From €16290EUR$17,995USD£13,981GBP
- Report
- July 2024
- 288 Pages
Global
From €5246EUR$5,998USD£4,350GBP
- Report
- May 2023
- 169 Pages
Global
From €2127EUR$2,350USD£1,826GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1358EUR$1,500USD£1,165GBP
- Report
- May 2025
- 134 Pages
Global
From €16290EUR$17,995USD£13,981GBP
- Report
- August 2025
- 150 Pages
Global
From €4391EUR$4,850USD£3,768GBP
Biktarvy is a combination drug used to treat HIV/AIDS. It is a single-tablet regimen that combines three antiretroviral drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Biktarvy is used to treat HIV-1 infection in adults and adolescents aged 12 years and older. It is also used to reduce the risk of HIV-1 infection in adults and adolescents who are at high risk of HIV-1 infection. Biktarvy works by blocking the action of the virus in the body, preventing it from multiplying and spreading.
The Biktarvy market is a rapidly growing segment of the HIV/AIDS drugs market. It is a highly competitive market, with several companies offering their own versions of the drug. Companies in the Biktarvy market include Gilead Sciences, Mylan, and ViiV Healthcare. Show Less Read more
